Search
EHA welcomes European Parliament backing for SoHO legislation
EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.
Read moreEuropean Scientific foundation for Laboratory Hemato Oncology (ESLHO)
The objectives of ESLHO are to promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies, as well as to facilitate quality control and education in this field.
Read moreChallenges and opportunities in the diagnostics and management of onco-hematological patients under the microscope during tutorial in Russia
Onco-hematology was the focus of the two-day EHA Hematology Tutorial in Moscow, Russia, the third joint tutorial organized by EHA, the National Hematological Society (NHS) and the Russian-Oncohematology Society (ROHS).
Read moreHighlights from the SWG
Most impactful activitiesHIV Registry (NCT05231135)This unique retrospective and prospective EHA LyG European registry was initiated in August 2021, but recruitment was stalled due to objections from the local Ethics Committee.
Read moreWhat an EHA Innovation Grant supports
Our EHA Innovation Grant supports high-quality clinical or translational research in hematology. To reflect the collaborative spirit of the grant, no more than 40% of the total grant should be allocated to one member of the consortium.
Read moreFundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report
Healthy subjects frequently report minor bleedings that are frequently ‘background noise’ of normality rather than a true disorder. Nevertheless, unexpected or unusual bleeding may be alarming.
Read moreWhat an EHA Bilateral Collaborative Grant supports
Our EHA Bilateral Collaborative Grant supports basic and translational lab-based research in hematology. To reflect the collaborative spirit of the grant, the budget must be divided 50:50 between the two PIs.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- »